Abstract
As the control of acute chemotherapy-induced emesis has improved, delayed emesis (occurring 24 h or more after treatment) has become the most bothersome vomiting problem. Delayed vomiting occurs after treatment with many anticancer drugs, but has been most often studied following cisplatin or combinations of cyclophosphamide and anthracyclines. The mechanism of this phenomenon is unknown. Empirical trials of antiemetic agents effective in controlling acute emesis identified the combination of metoclopramide and dexamethasone as useful in lessening delayed emesis after displatin in a randomized, placebocontrolled study. The specific serotonin receptor (5-HT3) antagonist ondansetron yielded results equivalent to the prior placebo results in a phase II trial using identical methodology in similar patients given cisplatin. Following anthracycline and cyclophosphamide combination chemotherapy, the delayed vomiting prevention observed with dexamethasone alone exceeds that of ondansetron. These observations suggest that delayed emesis is primarily mediated by neurotransmitters other than serotonin. Since delayed emesis occurs more frequently in patients who experience nausea and vomiting on the day they receive chemotherapy, tested combination antiemetic regimens, employing a 5-HT3 antagonist (either granisetron, metoclopramide, ondansetron or tropisetron), dexamethasone, and a benzodiazepine (lorazepam and alprazolam) should be routinely employed. This approach provides the best protection for acute and delayed emesis. Further research, looking beyond the specific 5-HT3 antagonists, provides the best strategy to improve the control of delayed symptoms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Clark R, Kris M, Tyson L, et al (1986) Antiemetic trials to control delayed vomiting following high-dose cisplatin. Proc Am Soc Clin Oncol 5:257
DeMulder PHM, Seynaeve C, Vermorken JB, et al (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 113:834–840
Florczyk AP, Schurig JE, Bradner WT (1982) Cisplatin-induced emesis in the ferret: a new animal model. Cancer Treat Rep 66:187–189
Gandara DR, Harvey WH, Monaghan GG, et al (1992) The delayedemesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol 19:67–71
Gralla RJ, Itri LM, Pisko SE, et al (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905–909
Grunberg SM, Ehler E, McDermed JE, et al (1988) Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin. J Natl Cancer Inst 80:864–868
Hayes D, Cvitkovic E, Golbey R, et al (1977) High dose cis-platinum diammine dichloride. Cancer 39:1372–1381
Herrstedt J, Sigsgaard T, Boesgaard M, et al (1993) Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 328:1076–1080
Jones AL, Hill AS, Soukop M, et al (1991) Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338:483–487
Kris MG, Gralla RJ, Clark RA, et al (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379–1384
Kris MG, Gralla RJ, Clark RA, et al (1987) Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenphydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 60:2816–2822
Kris MG, Gralla RJ, Clark RA, et al (1989) Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst 81:42–46
Kris MG, Gralla RJ, Tyson LB, et al (1989) Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide p0lus dexamethasone in patients receiving cisplatin. J Clin Oncol 7:108–114
Kris MG, Tyson LB, Clark RA, et al (1992) Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. Cancer 70:1012–1016
Marty M, Pouillart P, Scholl S, et al (1990) Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J med 322:816–821
McCallum RW (1991) Cisapride: a new class of prokinetic agent. Am J Gastroenterol 86:135–149
Roila F, Bracarda S, Tonato M, et al (1990) Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis. Clin Oncol 2:268–272
Roila F, Boschetti E, Tonato M (1991) Predictive factors of delayed emesis in cisplatin treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 14:238–242
Schmoll HJ (1989) The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes. Eur J Cancer Clin Oncol 25 [Suppl 1]:535–539
Strum S, McDermed J, Abrahano-Umall R, et al (1985) Management of cisplatin(DDP)-induced delayed-onset nausea (N) and vomiting (V): preliminary results with 2 drug regimens. Proc Am Soc Clin Oncol 4:263
Wilder-Smith OHG, Borgeat A, Chappuis P, et al (1993) Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 72:2239–2241
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kris, M.G., Pisters, K.M.W. & Hinkley, L. Delayed emesis following anticancer chemotherapy. Support Care Cancer 2, 297–300 (1994). https://doi.org/10.1007/BF00365581
Issue Date:
DOI: https://doi.org/10.1007/BF00365581